Theralase Technologies Inc. V.TLT

Quality of this NR is so much better

[N0taP00p]

They either hired someone new or spent time on fixing previous issues with their comms.   This NR is so much more clearer (the safety data paragraph,  what to expect next with BTD, etc).  I hope there's a patient advocacy group writing to the FDA to get this approved ASAP.

[riverrrow]

I'm sorry, but for me this news release is just a big yawn.  I was expecting some serious two and three year CR numbers.  I don't see this news attracting any new investors and the tradeable warrants are almost guaranteed to expire worthless.  I believe at the time of financing in 2019, for income tax purposes, the warrants were valued at 7 cents a warrant.  That's

[N0taP00p]

@riverrow: the market certainly seems to agree with you.

[DJDawg]

The market and wider stock buying groups out there still see a company with limited cash and no imminent catalyst (the BTD thing has been iterated so many times that it seems that it has been factored in as a vague item for the future). It will be interesting to see what happens when the big lump of warrants expire. In case that changes anything. Otherwise it will be price limbo till BTD.

[reconsider]

II see this a good, serious release. Goals still in Q3 and explanation on why the last delay (Post Study II Monitoring of Response and Central Pathology Laboratory Review). I believe that after the warrants expire we will see a SP climb in September-October. Still a chance that in the next couple of weeks we touch 9 cents... good news we already did today :)  Optimistic about Q4. GLTA

[Paradise818]

You're right.  The stock price is reflecting your conclusion.